The treatment of DPVD using SMTAD predominantly targets pathways related to cancer, lipid and atherosclerosis, the AGE-RAGE signaling pathway, the interleukin IL-17 signaling pathway, the tumor necrosis factor signaling pathway (TNF), the endocrine resistance pathway, the cellular senescence pathway, and 178 other pathways, as illustrated in Figure 6. This evidence concerns the gene TNF and atherosclerosis.